Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | BRD4 | O60885 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20942567 | 0.90 | USP2 (0.79) | USP2BRD4POLBTP53KDM4E | |
| SCHEMBL20942539 | 0.89 | BRD4 (0.60) | USP2BRD4POLBL3MBTL1ALDH1A1 | |
| SCHEMBL20942498 | 0.83 | POLB (0.82) | USP2BRD4POLBTP53L3MBTL1 | |
| SCHEMBL20942547 | 0.80 | BRD4 (0.67) | USP2BRD4POLBL3MBTL1ALDH1A1 | |
| SCHEMBL19276575 | 0.79 | BRD4 (0.60) | USP2BRD4POLBL3MBTL1MEN1 | |
| SCHEMBL20942582 | 0.78 | MAPT (0.59) | BRD4POLBTP53L3MBTL1 | |
| SCHEMBL20942516 | 0.77 | TAF1 (0.59) | BRD4POLBTP53ALDH1A1KDM4E | |
| SCHEMBL19276665 | 0.75 | SMN1; SMN2 (0.63) | BRD4L3MBTL1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL20942542 | 0.74 | TAF1 (0.65) | BRD4TP53ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL20942538 | 0.74 | NPC1 (0.60) | USP2BRD4TP53ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10702518-B2 | TAF1 inhibitors for the therapy of cancer | CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH (AT) | 2020-07-07 | — | — | US | disclosed |
| US-20190117641-A1 | TAF1 INHIBITORS FOR THE THERAPY OF CANCER | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117641-A1 | TAF1 INHIBITORS FOR THE THERAPY OF CANCER | TAF1, TAF1L, TAF5 | USP2 1764/4885BRD4 27/4885POLB 244/4885 |
| US-10702518-B2 | TAF1 inhibitors for the therapy of cancer | TAF1, TAF1L, TAF5 | USP2 1764/4885BRD4 27/4885POLB 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.